Patients with inflammatory bowel disease and post-inflammatory polyps have an increased risk of colorectal neoplasia: A meta-analysis

Table 3 The results of subgroup analysis in colorectal neoplasia and advanced colorectal neoplasia

Subgroup	Study	Pooled RR (95%CI)	P value	I2 value，%
Colorectal neoplasia
Study design
Cohort study	4	1.88 (1.18-3.00)	0.008	80.0
Case-control study	5	1.68 (1.20-2.35)	0.002	85.6
Methodological quality
Serious/Critical risk of bias	3	1.74 (1.00-3.01)	0.049	87.5
Low/Moderate/Unclear risk of bias	6	1.74 (1.28-2.36)	0.000	80.7
IBD phenotypes
UC	5	1.76 (1.18-2.63)	0.006	81.6
CD	NA	NA	NA	NA
UNCLASSIFIED IBD	NA	NA	NA	NA
Geographic regions
Europe	5	2.05 (1.62-2.59)	0.000	60.7
America	2	1.17 (0.86,1.59)	0.314	56.1
Asia	1	4.56 (1.93,10.79)	0.000	NA
Advanced colorectal neoplasia (ACRN)
Study design
Cohort study	3	2.42 (1.36-4.32)	0.003	40.1
Case-control study	3	1.92 (1.27-2.90)	0.002	88.6
Methodological quality
Serious/Critical risk of bias	1	2.11 (1.64-2.71)	0.000	NA
Low/Moderate/Unclear risk of bias	5	2.1 (1.35-3.27)	0.001	80.6

RR: Risk ratio; CRN: Colorectal neoplasia; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: Crohn’s disease; UNCLASSIFIED IBD: Unclassified inflammatory bowel disease; ACRN: Advanced colorectal neoplasia; NA: Not available.